Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2005 2
2006 1
2008 2
2009 2
2010 1
2011 5
2012 2
2013 6
2014 6
2015 2
2016 4
2017 3
2018 1
2019 5
2020 5
2021 16
2022 15
2023 12
2024 11

Text availability

Article attribute

Article type

Publication date

Search Results

87 results

Results by year

Filters applied: . Clear all
Page 1
Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma.
Loriot Y, Matsubara N, Park SH, Huddart RA, Burgess EF, Houede N, Banek S, Guadalupi V, Ku JH, Valderrama BP, Tran B, Triantos S, Kean Y, Akapame S, Deprince K, Mukhopadhyay S, Stone NL, Siefker-Radtke AO; THOR Cohort 1 Investigators. Loriot Y, et al. N Engl J Med. 2023 Nov 23;389(21):1961-1971. doi: 10.1056/NEJMoa2308849. Epub 2023 Oct 21. N Engl J Med. 2023. PMID: 37870920 Clinical Trial.
Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial.
Siefker-Radtke AO, Matsubara N, Park SH, Huddart RA, Burgess EF, Özgüroğlu M, Valderrama BP, Laguerre B, Basso U, Triantos S, Akapame S, Kean Y, Deprince K, Mukhopadhyay S, Loriot Y; THOR cohort 2 investigators. Siefker-Radtke AO, et al. Ann Oncol. 2024 Jan;35(1):107-117. doi: 10.1016/j.annonc.2023.10.003. Epub 2023 Oct 21. Ann Oncol. 2024. PMID: 37871702 Clinical Trial.
Second-line Pembrolizumab for Metastatic Urothelial Carcinoma: Differences in Treatment Outcomes According to the Primary Site.
Nishiyama N, Kita Y, Ito K, Kato M, Hatakeyama S, Matsushita Y, Naito S, Miyake M, Nakanishi S, Kato Y, Shibuya T, Hayashi T, Yasumoto H, Yoshida T, Uemura M, Taoka R, Nishiyama H, Kobayashi T, Kitamura H; Japan Urological Oncology Group. Nishiyama N, et al. Among authors: taoka r. Anticancer Res. 2023 Nov;43(11):5041-5050. doi: 10.21873/anticanres.16703. Anticancer Res. 2023. PMID: 37909969
Comparison of perioperative outcomes and complications between intracorporeal, extracorporeal, and hybrid ileal conduit urinary diversion during robot-assisted radical cystectomy: a comparative propensity score-matched analysis from nationwide multi-institutional study in Japan.
Morizane S, Nakane K, Tanaka T, Zennami K, Muraoka K, Ebara S, Miura N, Uemura K, Sobu R, Hoshi A, Taoka R, Sugimoto M, Noma H, Sunada H, Nishiyama H, Habuchi T, Ikeda I, Saika T, Makiyama K, Shiroki R, Masumori N, Koie T, Takenaka A. Morizane S, et al. Among authors: taoka r. Int J Clin Oncol. 2024 Jan;29(1):64-71. doi: 10.1007/s10147-023-02425-8. Epub 2023 Oct 21. Int J Clin Oncol. 2024. PMID: 37864612
Prognostication in Japanese patients with bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer undergoing early radical cystectomy.
Nishimura N, Miyake M, Iida K, Miyamoto T, Tomida R, Numakura K, Inokuchi J, Yoneyama T, Matsumura Y, Yajima S, Masuda H, Terada N, Taoka R, Kobayashi T, Kojima T, Matsui Y, Nishiyama N, Kitamura H, Nishiyama H, Fujimoto K. Nishimura N, et al. Among authors: taoka r. Int J Urol. 2022 Mar;29(3):242-249. doi: 10.1111/iju.14759. Epub 2021 Dec 13. Int J Urol. 2022. PMID: 34902876
87 results